机构：[1]Afliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China河南省肿瘤医院[2]Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China[3]Tongji Hospital, Tongji Medical College, Wuhan 430032, China华中科技大学同济医学院附属同济医院[4]Fujian Medical University Union Hospital, Fuzhou 35000, China[5]Zhejiang Cancer Hospital, Hangzhou 310000, China浙江省肿瘤医院[6]Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China[7]West China Hospital of Sichuan University, Chengdu 610041, China四川大学华西医院[8]The First Afliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China江苏省人民医院[9]The First Afliated Hospital, Zhejiang University College of Medicine, Hangzhou 310003, China[10]Fudan University Shanghai Cancer Center, Shanghai 200032, China[11]Nanfang Hospital of Southern Medical University, Guangzhou 510515, China[12]The First Hospital of Jilin University, Changchun 130031, China[13]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China[14]Peter MacCallum Cancer Centre, St.Vincent’s Hospital, University of Melbourne, Melbourne, VIC 3065, Australia[15]North Shore Hospital, Auckland 2065, New Zealand[16]The University of Texas MD Anderson Cancer Center, Houston, TX 78701, USA[17]University of Michigan, Ann Arbor, MI 48109, USA[18]Monash Health, Monash University, Clayton,VIC 3800, Australia[19]BeiGene (Beijing) Co.,Ltd, Beijing 102206, China[20]Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with a high initial response rate followed almost invariably by relapse. Here we report the pooled data from 2 studies, BGB-3111-AU-003 and BGB-3111-206, to explore the efficacy of zanubrutinib monotherapy in relapsed/refractory (R/R) MCL. A total of 112 patients were included. Median follow-up durations were 24.7 and 24.9 months for BGB-3111-AU-003 and BGB-3111-206, respectively. Overall response rate (ORR) and complete response (CR) rate were 84.8% and 62.5%, and median duration of response, progression-free survival (PFS) and overall survival (OS) were 24.9, 25.8 and 38.2 months, respectively. After weighting, the PFS (median: NE vs. 21.1 months, P = 0.235) and OS (median: NE vs. 38.2 months, P = 0.057) were similar but numerically better in the second-line than later-line group. Zanubrutinib was well-tolerated with treatment discontinuation and dose reduction for adverse events in 12.5% and 2.7% of patients, respectively. Hypertension, major hemorrhage and atrial fibrillation/flutter rates were 11.6%, 5.4% and 1.8%, respectively. Zanubrutinib is efficacious in R/R MCL, with a favorable safety profile.
第一作者机构：[1]Afliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China
通讯作者：
推荐引用方式(GB/T 7714)：
Keshu Zhou,Dehui Zou,Jianfeng Zhou,et al.Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials[J].JOURNAL OF HEMATOLOGY & ONCOLOGY.2021,14(1):doi:10.1186/s13045-021-01174-3.
APA：
Keshu Zhou,Dehui Zou,Jianfeng Zhou,Jianda Hu,Haiyan Yang...&Yongping Song.(2021).Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials.JOURNAL OF HEMATOLOGY & ONCOLOGY,14,(1)
MLA：
Keshu Zhou,et al."Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials".JOURNAL OF HEMATOLOGY & ONCOLOGY 14..1(2021)
医学